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Summary Photodynamic therapy (PDT) is a promising approach to the local destruction of malignant
tumours, but little work has been done to determine which factors control the extent of tissue necrosis
produced. Using a new photosensitiser, a sulphonated aluminium phthalocyanine (AlSPc) and light from an
argon ion pumped dye laser at 675 nm, we quantified the effects of interstitial PDT in a transplantable
fibrosarcoma in rats. At lOOmW laser power, thermal effects were comparable to those of PDT, so
subsequent studies were carried out at 50mW, where thermal effects were minimal. The depth of PDT
necrosis increased with the logarithm of the applied energy. Tissue concentration of AlSPc was measured by
alkali extraction and at all times after sensitisation, correlated well with the necrosis produced with a given
light dose. Peak tumour concentration of AlSPc occurred 24-48h after sensitisation compared with a peak at
3h in muscle. The peak ratio tumour:muscle was 2:1 at 24h. Apart from a different time interval to reach the
peak sensitiser concentration, the extent of tumour damage varied with the light and sensitiser parameters in a
similar way to that found in normal liver, although the optical penetration depth was greater in the tumour
(2.5mm vs. 1.8mm). At doses of AlSPc below 1 mgkg- the diameter of necrosis increased with the
logarithm of the dose of sensitiser, and doubling the dose from 0.25 to 0.5 mgkg- increased the depth of
necrosis by 50%. However, at higher doses, the changes were smaller and increasing the dose from 2.5 to
5mgkg-1 only increased the necrosis by 10% for the same light dose. In all dose ranges, a given percentage
increase in the tissue concentration of AlSPc gave a much smaller percentage increase in the extent of necrosis
for the same light dose, suggesting that selectivity of necrosis between tumour and normal tissue is likely to
be much less than the selectivity of retention of the photosensitiser. From these results, the extent of PDT
necrosis in this fibrosarcoma is as predictable as it is in normal liver if the light dose, tissue concentration of
AlSPc and optical penetration depth of the tissue are known. Further studies are now required on different
tumour models to establish how tumours respond compared with adjacent normal tissue when the tumour is
growing in its organ of origin rather than the non-physiological situation using a transplantable tumour as in
this study.
Photodynamic therapy (PDT) is a method of treating
tumours by the combined use of systemically administered
photosensitisers and the local application of light. It has
been suggested that porphyrins, in particular haemato-
porphyrin derivative (HpD), accumulate selectively in
malignant tissue, so causing these tumours to fluoresce
(Gregorie et al., 1968). When irradiated with an appropriate
wavelength of light these photosensitisers are excited to the
triplet state which is then capable of reacting directly with
tissue components or undergoing interaction with molecular
oxygen in order to produce cytotoxic species such as singlet
oxygen and free radicals (Weishaupt et al., 1976). Most of
the work reported to date has used HpD (Lipson et al.,
1961) as the sensitiser, but HpD is far from ideal. It is a
mixture of porphyrins, it is difficult to keep its composition
the same in different batches, tumour selectivity is poor and
it only has a weak absorption peak in the red area of the
spectrum where tissue penetration is high. For these reasons
we decided to look closer at a new group of photosensitisers,
the phthalocyanines. In a recent review of phthalocyanines,
Spikes (1986) suggests that these compounds could be
valuable sensitisers for PDT of tumours. A number of
studies have shown that various phthalocyanines (PC) will
photosensitise the killing of mammalian cell lines in culture.
Ben-Hur and Rosenthal (1985, 1986) have reported studies
on Chinese hamster fibroblasts V-79, using chloraluminium
PC(CAPC), tetrosulfo PC (TSPC) and its metal chelates.
They reported that the metal free dye (TSPC) was 4 times
more effective than haematoporphyrin (HP) and chelation
with metal ions generally resulted in diminished photo-
sensitising capacity except with cerium. The cerium
derivative was 5 times more effective than the metal free
PCs. Chan et al. (1986) used aluminium chloro sulphonated
PC (AlSPc) with two murine cell lines NlH/3T3 ('normal
fibroblast line') and UV-2237 (a 'transformed' fibrosarcoma
line) to study cell killing and uptake of the AlSPc. Both lines
behaved similarly and those sensitised with AISPc were killed
more rapidly by light than those treated with a similar dose
of HpD.
A number of phthalocyanines have been shown to be
selectively retained in malignant tissues. Frigerio (1962)
showed selective uptake of water soluble SPC in inplanted
brain tumours of mice and reported a ratio tumour:normal
brain of 50:1. Rousseau et al. (1983, 1985) and Van Lier &
Rousseau (1984) used technetium (99mTc) and gallium (67Ga)
radiolabelled TSPC in the 13762 mammary adenocarcinoma
of Fischer 344/CRBL rats. Tc-TSPC achieved ratios of 3.8:1
tumour:muscle at 24h post-sensitisation and Ga-TSPC
achieved a ratio of 15: 1 tumour:muscle at 6h post-
sensitisation. Straight and Spikes (reported in Spikes, 1986)
found selective retention of zinc SPc in S180 tumours of
Swiss Webster mice although the tumour:normal tissue ratio
is not stated nor is the time at which maximum selectivity is
found. We have shown selective retention of AlSPc in
dimethylhydrazine induced colon tumours in Wistar rats, a
ratio of 2:1 tumour:normal colon being found at 24-48h
(Tralau et al., 1986) and we have also shown a 2:1 ratio,
tumour:muscle in a fibrosarcoma of rats at 48h as described
later in this paper. Little data have yet been reported on in
vivo phthalocyanine phototherapy. Spikes (1986) reports a
personal communication from Van Lier indicating that metal
free, TSPC, AITSPC, cerium TSPc and HpD (Photofrin II)
have been compared as photosensitisers of a mouse
(BALB/c) mammary tumour (EMT-6) and that AITSPC is
as effective and cerium TSPc more effective than HpD. In
the same paper Spikes also reports studies of ZnSPc as a
sensitiser of implanted S180 tumours in mice. They have
shown that 220J/CM2 of 650nm laser light decreases the
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tumour volume by 50% whereas a dose of 360 J/CM2 of
630 nm light is required to produce the same effects with
HpD. Unfortunately the doses of sensitisers used are not
reported nor is the laser power and for meaningful results
the doses must be comparable, and hyperthermic effects
eliminated. There have been few quantitative studies done on
photodynamic therapy. In 1984 we reported preliminary
quantitative studies in liver, muscle and fibrosarcoma of
CBH rats (Coleridge-Smith et al., 1984). At 48 h after
sensitisation with 20mgkg-1 HpD given i.v., all 3 tissues
studied had a similar area of necrosis for similar light doses.
Pimstone et al. (1982) showed that with haematoporphyrin
sensitisation the depth of necrosis in normal liver increased
with the natural logarithm of the applied energy and we
showed similar results in normal liver with both HpD and
AISPc sensitisation (Bown et al., 1986). Analysis of the
parameters involved showed that the factors which effected
the extent of PDT necrosis were: (1) Dose of sensitiser; (2)
Time from sensitisation to phototherapy; (3) Power and
exposure time of light source; (4) Circulation through the
tissue during light exposure.
AlSPc was chosen for our studies because it is easy to
synthesise, chemically stable and has a strong absorption
peak (Q band) in the red part of the spectrum at 675nm in
aqueous solution. It has a good fluorescence quantum yield
(0.6) in aqueous solution needed for fluorescence localisation
of tumours; and has a good triplet quantum yield (0.4) with
a long lived triplet state (510+50,uSEC, pH7.4) which is
capable of undergoing energy transfer to produce cytotoxic
species (McCubbin, 1985). The purpose of this paper is to
look at which parameters effect the extent of PDT induced
necrosis in malignant tissue (the transplantable fibro-
sarcoma) in rats and to compare the results with those
obtained previously in normal liver. Such a study has not
been reported before.
Materials and methods
Tumour model
The tumour model used throughout was a transplantable
fibrosarcoma (HSN/TC/7) of CBH rats. Solid tumour tissue
(I g) was removed immediately after killing the donor animal
and mechanically disaggregated in a laboratory mixer
emulsifier (Silverson Machines Ltd.) on medium speed in
lOml of 0.9% saline. This solution (0.1 ml) was injected s.c.
into both flanks of rats anaesthetised with i.m. hypnorm
0.5mlkg-1 (fentanyl and fluanisone). Rats were given food
and water ad libitum. The tumour took 10-12 days to grow
to 6-10mm in diameter. This size was used for quantitative
studies as no spontaneous necrosis was seen. At larger
diameters, spontaneous necrosis was seen frequently making
quantitative studies difficult, although it was usually possible
to tell the difference between spontaneous and PDT induced
necrosis on histological grounds.
Photosensitiser
Aluminium chloro sulphonated phthalocyanine (AlSPc) as
supplied by Ciba Geigy was used. This has an average of 3
sulphonic acid groups per molecule (McCubbin, 1985). This
was dissolved in 0.9% saline and administered by i.v.
injection into a tail vein. Sensitised animals were kept in
subdued lighting.
Pharmacodynamics ofAISPc
The concentration of AlSPc was measured in tumour,
adjacent muscle and skin and in plasma at various times
from a few minutes to 120h post sensitisation with
5mgkg- 1 AlSPc and in tumour after sensitisation with
various doses of AlSPc (0.2-25mgkg-1). Rats were killed by
cervical dislocation and -0.5g each of tumour, underlying
muscle and overlying skin were removed and kept frozen at
-20°C until extraction. Tissue samples were weighed, finely
chopped and homogenised in 7 ml of 0.1 M NaOH for 2min.
The homogenate was centrifuged at 12,000rpm for 5min at
4°C, the clear supernatant separated, and the fluorescence
read at 675nm on a spectrofluorimeter (Perkin Elmer LS-5
Luminescence Spectrophotometer) with excitation at 610nm.
We have previously shown that this is an efficient extraction
procedure (Bown et al., 1986). The effect of quenching of
fluorescence of solutions of known concentrations of AISPc
in 0.1 M NaOH was compared with that from the same
concentrations of AISPc when present in the supernatant
from the extraction procedure on unsensitised tissues. The
percentage quenching found remained the same throughout
the standard curve and the mean quenching for each tissue
was 18% (tumour), 19% (skin) and 16% (muscle). In order
to correct for this all results from sensitised tissues were
calibrated against a standard curve of known concentrations
of AlSPc in tissue supernatant (unsensitised) and expressed
in micrograms of AISPc extracted per gram of tissue.
Phototherapy
The light source used was an argon ion pumped dye laser
(Aurora-Cooper Lasersonics). The dye used was DCM (4-
dicyanomethylene-2-methyl-6-(p-dimethylaminostyryl)-4H
pyran in ethylene glycol and propylene carbonate) and the
laser was tuned to emit light at 675 nm. The light was
delivered via a 0.2mm diameter quartz fibre with a plastic
coating left on to within 1 mm of the fibre end to prevent
emission of light from any region other than the last 1 mm.
The fibre was cleaved as often as necessary to obtain a clean
circular light beam and the power checked in a power meter
(photon control) prior to each treatment. Animals were
anaesthetised as for sensitisation, the skin of the area
surrounding the flank tumours was shaved and the tumour
exposed by a single incision of the overlying skin. The size of
the tumours was measured in three dimensions, using
calipers, although most were roughly spherical. The 'capsule'
of the tumour was pierced with a needle point and the fibre
inserted into the middle of the tumour mass. Control experi-
ments using 50 and 100mW were done in unsensitised
animals to establish the power at which purely thermal
effects could be seen. FiftymW was chosen as the power
which limited thermal effects to a zone <2mm in diameter
around the fibre tip and which did not cause charring. The
laser was therefore set prior to fibre insertion to give a
power output of 50mW at the fibre tip for the quantitative
studies in sensitised animals. After exposure the fibre was
removed, the skin incision sutured and the animal allowed to
recover from the anaesthetic. The animals were re-anaesthe-
tised and given an i.v. injection of Evans blue a few minutes
before death (I ml 0.5% Evans in 0.9% saline) to facilitate
subsequent identification of necrotic areas. Animals were
killed by cervical dislocation at various times from treatment
(0.1-96h) and tumour tissue removed immediately, fixed in
10% formalin, sectioned at 1 mm intervals and the maximum
and minimum width of macroscopic necrosis (white area)
was measured in each slice. The highest mean value (average
of maximum and minimum) was recorded. Representative
sections were sent for histological examination. Micro-
scopically measured areas correlated well with those
measured macroscopically. At the power level where thermal
effects were negligible, experiments were carried out to
investigate the effects of the following parameters on the
extent of necrosis produced:
(1) Laser energy (1 to 200J), for one laser power (50mW),
one dose of sensitiser (5 mgkg-1), and at one time from
sensitisation to phototherapy (3 h).
(2) Dose of sensitiser (0.2mgkg -1 to 25mgkg- 1) for one
laser power (50mW) one energy (50J) and one time from
sensitisation to phototherapy (3 h).
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72h) at one dose of AISPc (5mgkg 1) and one laser power
(50mW) and one energy (50J).
Results
The AlSPc pharmacodynamic results given are those for
extractable fluorescence of phthalocyanine when excited at
610nm and emission read at 675nm. Although the AISPc
solution consists of only aluminium chloro sulphonated
phthalocyanines, it contains varying numbers of sulphonic
acid groups (-SO-) per molecule. It is understood that the
number of -SO3 groups will effect the distribution within
the animal so the results are given as the best approximation
for the combination of phthalocyanine species present in the
tissues.
The quantity of AlSPc extracted from tumour, overlying
skin and underlying muscle as a function of time from
sensitisation is summarised in Figure 1 and detailed in Table
I. The concentration of AlSPc peaks in tumour tissue at 24-
48h post-sensitisation whereas muscle peaks after 3h. The
total quantities are higher in skin than tumour and muscle
throughout the time period studied. A similar pattern was
found for skin and muscle in non-tumour animals.
Figure 2 Section of treated tumour following i.v. administration
of Evans blue 10min before death and subsequent fixation in
formalin. The area of PDT necrosis (N) is distinguishable from
viable tumour (T) ( x 8).
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Figure 1 Concentration of extractable AlSPc in tumour (0),
muscle (0), skin (D) and plasma (A) following i.v. adminis-
tration of 5mgkg-1 AlSPc.
The maximum tumour:muscle ratio is achieved at 24-48h
and is 2:1. The plasma data is shown for comparison. An
example of macroscopic tumour necrosis brought out by the
Evans blue stain is shown in Figure 2. The relationship
between mean width of necrosis and applied energy
(=power x time) at a power of 100mW and 50mW is shown
in Figures 3 and 4 respectively, for an AlSPc dose of
5mgkg-1 and time from sensitisation to treatment of 3h. It
can be seen that the control value (unsensitised tumour) at a
power of 100mW, and energy 50J is 4.5mm mean diameter
whereas the control value at 50mW for the same energy is
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Figure 3 Mean diameter of laser induced necrosis in tumour as
a function of applied energy for exposure at a laser power of
100mW, 3h after sensitisation with 5mgkg- 1 AlSPc (0);
controls in unsensitised tumours are also shown (Q). Each point
represents the mean (±s.d.) of at least 5 animals.
Table I Concentration of extractable AISPc in skin, tumour, muscle and
plasma, measured by alkali extraction after i.v. administration of 5mgkg-1
(N) i+s.d.
AlSPc
Timefrom
administration Tumour Muscle Skin Plasma
(h) ,igg 1 igml-
0.1 - (3) 2.7+0.5
1 (4) 2.9+0.3 (4) 2.3+0.8 (4) 5.7+1.3 (3) 1.2+0.5
3 (3) 3.0+0.3 (3) 3.2+0.3 (3) 4.9+2.3 (3) 0.5+0.7
24 (3) 3.1 + 1.0 (4) 2.3+ 1.7 (4) 5.4+2.0 (3) 0.3
48 (3) 3.9+0.5 (3) 1.4+0.6 (2) 4.4+1.5 (3) 0.0
72 (4)2.8+0.3 (4) 1.4+0.5 (4)4.8+1.6 (3)0.0
96 (4) 1.4+0.2 (4) 2.3+0.5 (4) 4.6+0.6 (3) 0.0
120 (4)2.1+0.8 (4)2.1+1.8 (4)4.2+1.4 (3)0.0
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Figure 6 Mean diameter of laser induced necrosis in tumour
(5OmW, 50J, 3h after sensitisation) as a function of adminis-
0 tered dose of AlSPc (0); control value in unsensitised tumour is
also shown (0).
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Figure 4 Mean diameter of laser induced necrosis in tumour as
a function of applied energy for exposure at a laser power of
50mW, 3h after sensitisation with 5mgkg-1 AISPc (0);
controls in unsensitised tumours are also shown (0). Each point
represents the mean (±s.d.) of at least 5 animals.
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Figure 7 Concentration of extractable AlSPc (pgg -I tissue) as a
function of dose, 3 h after administration. Each point represents
the mean of 2 tumours. I
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Figure 5 Mean diameter of laser induced necrosis in tumour
(50mW, 50J) as a function of the time from sensitisation (AlSPc
5 mgkg- 1) to light exposure. Each point represents the mean
(±s.d.) from at least 3 animals.
only 2.5 mm. Thermal effects are obviously involved at
lOOmW and as we wished to investigate effects due to PDT
alone a power of 50mW was used for all further work to
minimise thermal necrosis. The variation of mean width of
necrosis in relation to time from sensitisation to photo-
therapy is shown in Figure 5. The maximum width of
necrosis was seen when phototherapy was carried out 24h
post sensitisation. The effect of varying the dose of AlSPc
(0.2 to 25mgkg-1) on mean width of necrosis is shown in
Figure 6. The concentration of AlSPc in tumours 3h after
the administration of various doses of AlSPc (0.2 to
25 mgkg-l) is shown in Figure 7.
The aim of this paper was to establish whether the
parameters controlling the extent of PDT necrosis in
malignant tissue are the same as those controlling the
damage in normal tissue, that we have reported previously in
studies on the liver (Bown et al., 1986). The factors involved
can be divided into those related to the light dose and the
sensitiser.
Light dose
Using the interstitial method of treatment with the laser fibre
inserted into the target tumour, it is inevitable that some
thermal effects will be seen in the immediate vicinity of the
fibre tip. In liver, at a laser power of 100mW, thermal
damage in unsensitised animals was limited to a zone about
2mm in diameter, so the greater damage seen in sensitised
animals could be attributed to photodynamic effects.
However, in the tumour model at the same power, the zone
of necrosis increased in diameter with increasing energy even
in unsensitised animals (Figure 3) showing the tumour to be
more sensitive to hyperthermia than the liver. There are
several possible explanations for this. These tumours are
known to develop spontaneous central necrosis when over
1 cm in diameter so even when less than this size, as used in
these experiments, the centre, where the fibre tip is located
during therapy, may be more vulnerable to thermal damage
392 C.J. TRALAU et al.
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than normal liver. Also, the high blood flow in liver may
remove heat from the zone around the fibre tip more
effectively, although our previous studies occluding the blood
supply to the liver during phototherapy did not show any
increase in thermal damage in the liver without blood flow.
However, the most important conclusion from these results
is that the threshold power for thermal damage varies
between different organs. In our tumours, if the power was
kept down to 50mW, thermal damage was limited to a zone
of about 2mm in diameter, so any greater damage could be
attributed to photodynamic effects.
With the assumption that a threshold energy dose WT for
necrosis by PDT is reached at the edge of the necrotic zone,
using diffusion theory (Svassand et al., 1984) W, is related to
r, the radius of the necrotic zone according to:
WT=A(W /r)exp(-(r-d)ld)
where WO' is the total energy dose, d is the penetration depth
and A is a constant. From our previous analysis (Bown et
al., 1986) this expression can be rearranged when r d to give
with good approximation
2r=dIn WO+Constant
From Figure 4, for energies over about 10J this gives a value
of d= 2.1 +0.3mm for the tumour. Alternatively, without
making approximations the expression is simply rearranged
to give,
r=dIn(IW4/r)+Constant
Note however that errors in the value of r now appear in
both sides of the equation. Analysis of the data for WO' and r
yields a value of d= 1.8+0.3mm which is close to that
derived with the first method which although approximate
has the merit of facilitating interpretation of the energy dose
dependence shown in Figure 4.
Thse use of diffusion theory is however only valid for
values of r where the light distribution has become isotropic
through scattering. In practice, close to the fibre tip, the
distribution is not isotropic as the beam is roughly colli-
mated as it emerges from the fibre (Svaasand & Ellingsen,
1983). This would explain the necrosis observed at the
relatively low energy of 1J. This value of d, "2mm, may
also be an underestimate due to significant absorption by the
AlSPc, as discussed below. The data shown in Figure 3 for
100mW are more difficult to interpret since thermal effects
cannot be ignored and there is the possibility of charring or
coagulation occurring at the fibre tip which would alter and
distort the light distribution. Even though the optical pene-
tration of light at 675 nm is greater in tumour than liver, the
absolute quantity of AlSPc is less in tumour than liver
(1:2.7, 3 h after 5mgkg-1 AlSPc). The size of the necrotic
zone depends on both factors and in this case is slightly
wider in tumour than it is in liver for the same energy
(8.5 mm vs. 7.5mm, for 100J 3h after 5mgkg-1 of AlSPc).
The extent of necrosis around one treatment site can be
increased with higher energies, but as the power cannot be
increased without introducing thermal effects, extremely long
exposure times would be necessary, and it would be much
easier to treat larger volumes by using multiple treatment
sites.
There have been several reports that PDT and hyper-
thermia are synergistic and there is certainly evidence to
support this (Henderson et al., 1985), but until the effects of
both are more fully understood, we feel it is wise to restrict
studies to situations in which only one form of tissue
damage is investigated at a time. If the tumour to be treated
is very close to the surface, the light can be delivered without
the need for a fibre to be in direct contact with tissue, and a
larger area can be illuminated from a single light source
without the need for multiple fibres. Indeed, this is the
approach taken for most experimental and clinical work with
PDT. The risk of thermal effects is much less, but is
certainly still present and control studies are always
necessary to see whether they are occurring or not. Also, it is
often difficult to achieve a uniform light intensity across an
extended surface. The depth of tissue necrosis, as for
interstitial treatment, will depend on the optical penetration
depth, the light -fluence and the local concentration of
sensitiser. Although the geometry is different, the depth of
necrosis is likely to be comparable to the radius of necrosis
around an interstitial fibre for similar treatment parameters.
This means that for easily achieved light levels, the iepth of
necrosis is likely to be less than 5mm from the surl.tec.
Sensitiser
The pattern of AlSPc accumulation in this fibrosarcoma is
that of a gradual increase to a peak at 24-48h after
administration followed by an equally gradual decrease
(Figure 1). The concentration of plasma AlSPc is at its
highest at 0.1 h after sensitisation: it is therefore unlikely that
the tumour peak is due to plasma levels. AlSPc, which is
initially bound to plasma proteins (W.S. Chan, Personal
Communication) is taken up from the plasma into the
tumour tissue possibly by non-specific binding of serum
proteins to stromal elements and leaky vasculature (Bugelski
et al., 1981). The slow release of AlSPc from tumour tissue
may be due to (i) poor lymphatic drainage (Bugelski et al.,
1981); (ii) binding to tissue components such as (a) lipo-
protein receptors (Jori et al., 1984); or (b) collagen and
elastin (El Far & Pimstone, 1985). However, details of the
factors controlling the tissue distribution of these photo-
sensitisers are still poorly understood.
The tumour we used is transplantable and fast growing
and may behave quite differently from human neoplasms.
Nevertheless, studies such as the present one require similar
tumours in a large number of animals which is only possible
with a tumour model such as the one used. In addition, the
peak ratio of AlSPc concentration we found between tumour
and muscle (2:1 at 24-48h post sensitisation) is comparable
to our results for an autochthonous tumour (colon cancer
induced by dimethylhydrazine in rats) in which the peak
ratio between tumour and normal colon was also 2:1 at 24-
48h post sensitisation (Tralau et al., 1986). This compares
well with results reported for HpD. In dimethylhydrazine
induced colonic tumours of mice the ratio was 1.8:1 at 72h
post i.p. administration of 10mgkg-1 HpD (Agrez et al.,
1983) and a similar ratio, 1.8:1 (tumour:muscle), was
reported in methylcholanthrene induced mammary carcinoma
of mice 24h post i.p. administration of 10mgkg-1 HpD
(Gomer & Dougherty, 1979).
It is reassuring that the concentration of AlSPc measured
by extraction at different times after sensitisation correlates
well with the extent of the necrosis produced by a given light
dose (50J at 50mW) at the same times after sensitisation
(Figures 1 & 5). The peak concentration was seen 24-48h
after sensitisation, and maximum necrosis with a 24h
interval. We found the same correlation in the studies on
normal liver, although in liver the maximum of both extract-
able concentration of AlSPc and necrosis was spread over a
much longer time period.
The total dose of AlSPc influences the extent of PDT
damage as shown in Figure 6. At 0.2mgkg-1 the necrosis
does not differ significantly from that in unsensitised
animals, but at higher doses increases up to the maximum
dose tolerated by the animals, which was 25mgkg-1. In
liver, the extent of necrosis for a given light dose fell for
doses above 5mgkg- due to absorption of light by the
large amounts of AlSPc in the tissue which reduced the
optical penetration depth. This was not seen in the tumours
presumably because the dose required to achieve this was
above the dose that would kill the animal by a direct toxic
effect although at the higher doses of AlSPc the damage394 C.J. TRALAU et al.
does not increase so rapidly with the dose as it does at the
lower doses.
For photosensitiser doses which are sufficiently low for the
tissue absorption to be dominant over that of the photo-
sensitiser, the light energy required to cause necrosis is
WO = KtC (1)
where C is the photosensitiser concentration (Mgg-') p is the
energy flux density or space irradiance, t is the irradiation
time and K is a constant which depends on several factors
including the sensitiser absorption coefficient and singlet
oxygen yield (Profio & Doiron, 1981). At the edge of the
necrosis zone of radius r, the space irradiance is given by:
Tr = A(d/r) exp(-(r -d)/d) (2)
where A is a constant and d is the optical penetration depth
at the wavelength of the light source (Svaasand et al., 1984).
In the case where the total delivered light dose remains
constant substitution of (2) in (1) gives:
C =B(r/d) exp((r -d)/d) where B is a constant.
This assumes that the photosensitiser absorption is small
enough to neglect a change in the value of d. Thus:
ln C =ln(rld) +(r -d)/dt + ln B
When rt d this expression may be simplified using the
approximation
lnrldtrld-I
so that
ln C =2r/d-2 + ln B
and
2r=dlnC+2d-dlnB
Thus for the given conditions with a constant total energy
delivered from the fibre, the diameter of the necrotic zone
will increase approximately with the logarithm of the photo-
sensitiser dose with gradient d, the penetration depth. From
Figure 6 for doses less than 1 mgkg-' the diameter of
necrosis increases with the logarithm of the dose with an
approximate gradient of 2.5 but at higher doses shows a
reduced rate of increase with dose. These lower than
expected values found at higher doses can be ascribed to
light attenuation by the AISPc itself which absorbs strongly
at 675 nm (the molar extinction coefficient in aqueous
solution is 1.7 x 1- M- cm- (Darwent et al., 1982).
To model the dependence of necrosis on dose when the
sensitiser absorption is significant requires measurement of
several parameters including the sensitiser absorption
coefficient in the tissue, and the tissue absorption and
scattering coefficients. The possibility of sensitiser photo-
decomposition should also be taken into account. These
measurements have not been made, but several conclusions
of practical importance can be made on the basis of the
present analysis and the data in Figure 6. Firstly, it is clear
that at the higher doses of AlSPc, absorption of light by the
AlSPc itself does become comparable with the tissue
absorption to explain why the graph flattens at the higher
doses, instead of remaining linear. This could also explain
why the value of d from Figure 6 (2.5 mm) is greater than
that obtained from Figure 4 (2.1 mm) as in the latter case,
the dose of AlSPc used was 5mgkg-1, which is high enough
for absorption by the AlSPc to be significant compared with
that by the tumour itself, and so reduce the overall pene-
tration depth. Thus, when the AlSPc dose increases from
0.25 to 0.5mgkg-1, the width of necrosis increases from 3.3
to 5.0 mm (50%). However, when the dose increases from 2.5
to 5 mgkg-1, the necrosis only rises from 6.0 to 6.6mm
(10%). It can be seen from Figure 7 that the amount of
extractable AlSPc 3 h after administration was approximately
proportional to the administered dose, at least for doses
below 5 mgkg- 1. Therefore Figure 6 also represents the
relationship between the tissue concentration of AlSPc at the
time of light exposure and the resultant necrosis. For
maximum selectivity of tumour damage relative to adjacent
normal tissue one wants the maximum difference in necrosis
for a given difference in tissue concentration of sensitiser. It
is clear that this occurs on the linear portion of Figure 6 at
the low doses of AlSPc where absorption by AlSPc is small
compared with absorption by the tumour itself. No
comparable studies have been performed with HpD, but the
one other study that looked at the effect of varying the dose
of sensitiser (Pimstone et al., 1982), showed that the depth of
necrosis in normal liver also increased with the logarithm of
the dose of sensitiser (haematoporphyrin, in that case).
However, the absorption coefficient of HpD at 630nm is
much lower than that of AlSPc at 675nm, so absorption by
HpD may not be comparable to that of the tissue itself until
much higher tissue levels are reached. This means that
tumour selectivity with HpD will not depend so critically on
the dose of HpD used as is the case for AlSPc. However,
high doses of HpD cause major problems of cutaneous
photosensitivity, and so are best avoided if possible. In
normal liver, the light energy required to produce a zone of
necrosis 4mm wide is 10 times greater 3h after sensitisation
with 5mgkg-1 HpD than it is 3h after the same dose of
AlSPc.
El Far and Pimstone (1985) reported that a number of
tumour localising porphyrins (Uroporphyrin, HpD,
Photofrin II) have a high affinity for collagen and elastin
and AlSPc may bind to these components of skin. A major
problem of PDT using HpD is skin photosensitivity and as
there are high levels of AlSPc in skin one might expect skin
photosensitivity to be a major problem with this sensitiser as
well. When mice were given [14C] and [3H]-HpD at a dose of
10mgkg- i.p., lower absolute levels were found in the skin
(Gomer & Dougherty, 1979) than we found with AlSPc
(5mgkg-1, i.v.). However, during our earlier experiments it
was noted empirically that animals sensitised with 5mgkg-I
HpD had a greater cutaneous photosensitivity reaction in
room light than those sensitised with the same dose ofAlSPc
(Bown et al., 1986). Also, Chan et al. (1986) reported that
cells incubated in AlSPc were killed when irradiated at
675nm but were less sensitive to white light than cells
treated with equal concentrations of HpD. Thus, the high
levels of AlSPc found in skin may not be as much of a
problem as would be expected, but more detailed studies of
the skin response to light in sensitised animals- are required
to clarify this.
In conclusion, this study has shown that the extent of
PDT necrosis varies with the dose of sensitiser (AlSPc), and
the laser power and exposure time in a similar way in
normal liver and in a transplantable malignant tumour. It
has also shown that there is good correlation of tissue
damage with the tissue concentration of sensitisor at the time
of phototherapy (as measured by alkali extraction). Thus it
is possible to predict the extent of necrosis that will be
produced with given treatment parameters in both normal
and neoplastic tissue which is a significant step forward.
AlSPc distribution studies have shown a peak ratio of 2:1
between fibrosarcoma and muscle and between colon cancer
and normal colon which is comparable selectivity to that
shown with HpD. The difference in tissue damage for a
change in tissue concentration of sensitisor by a factor of 2
is greater when the absolute values of tissue levels of AlSPc
are lower rather than higher, but even so, is less than 2, 1.5
being the greatest ratio shown in this study.
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means. More selective tumour retention of the sensitiser
might be achieved by administering the sensitiser in
liposomes (Jori et al., 1986) or bonded to monoclonal
antibodies (Mew et al., 1983). Also selectivity can be
increased by directing the therapeutic light at the tumour
and not at the surrounding normal tissue, although to
eradicate a tumour locally, the most important area to treat
is where that tumour meets the normal tissue. The other
possibility is that the normal and tumour areas will respond
differently to the same local light fluence and concentration
of sensitiser. This is best tested in autochthonous tumours,
so the tumour develops in its organ of origin instead of
being transplanted, but no such work has yet been reported.
Of course, it does not matter if both normal and tumour
tissue are destroyed if the tumour is completely ablated,
normal tissue regenerates, and adequate structure and
function of the treated organ is maintained at all stages of
healing. However, for this to be achieved, further detailed
studies are required of the healing of relevant normal tissues
after PDT damage.
Overall, these results suggest that destruction of malignant
tumours based on selective retention of photosensitisers in
the neoplastic areas is likely to have less selectivity than has
been claimed hitherto. Nevertheless, local non-thermal
tumour destruction of predictable extent is possible and the
technique of PDT warrants further laboratory investigation,
particularly to study the response of small tumours induced
in clinically relevant organs such as the colon, bladder, lungs
and pancreas.
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